A Phase 3, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS‑CoV‑2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine with Matrix-M™ Adjuvant in Participants

  • Manners, David (Investigator 01)

Project Details

StatusActive
Effective start/end date1/08/24 → 31/12/26

Funding

  • PPD PTY LTD: A$45,000.00